Back to mobile site

More on RCUS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+30.7% Growth)
- Ratings (8.3 Score)
- Holders

Upcoming Events

- Earnings (11/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Arcus Biosciences (NY:RCUS)
Delayed: 21.75 -2 (8.42%)
Prev. Close $23.75  
Open$24.47 
52 Wk High$ 
52 Wk Low$ 
Day High$24.47 
Day Low$21.67 
P/E N/A  
EPS$ 
Volume649,442 

Friends, Peers and Foes (?): 0A3M, BMS, BMY, 4RY SMMT (more...)

Oct 21, 2026 07:05 AM Arcus Biosciences (RCUS) PT Raised to $41 at Truist Securities
Oct 21, 2026 03:56 AM Citi raises Arcus Biosciences price target to $50
Oct 20, 2026 01:32 PM Arcus Biosciences (RCUS) PT Raised to $49 at Wedbush
Oct 20, 2026 09:12 AM Arcus stock tumbles 6% after unveiling casdatifan trial data
Oct 20, 2026 08:33 AM Form 8-K Arcus Biosciences, Inc. For: Oct 20
Oct 20, 2026 08:31 AM Arcus shares kidney cancer trial data for casdatifan drug
Oct 20, 2026 08:30 AM Arcus Presents New Data from ARC-20 that Demonstrate the Opportunity for Casdatifan to Become a Foundational Treatment Across All Lines of Therapy in Kidney Cancer
Oct 16, 2026 03:14 AM William Blair Starts Arcus Biosciences (RCUS) at Outperform
Oct 14, 2026 02:51 AM JPMorgan Starts Arcus Biosciences (RCUS) at Overweight
Oct 9, 2026 04:35 PM Arcus Biosciences Announces New Employment Inducement Grants
View All Articles

Entities mentioned with RCUS

View All Entities